先健科技主动脉弓支架系统获批 国内首创盘中涨超3%

iDoNews
23 May

2025年5月14日,先健科技宣布其主动脉弓支架系统获国家药监局正式注册批准。该产品是国内首款使用开窗技术进行主动脉弓分支重建的覆膜支架系统,适用于Stanford B型主动脉夹层患者的治疗。系统由AnkuraTM Plus和CSkirtTM组成,临床数据显示术后1年分支血管通畅率达99.1%。受此利好消息影响,先健科技股价盘中涨超3%,现报1.60港元。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10